JP2015505553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505553A5 JP2015505553A5 JP2014555212A JP2014555212A JP2015505553A5 JP 2015505553 A5 JP2015505553 A5 JP 2015505553A5 JP 2014555212 A JP2014555212 A JP 2014555212A JP 2014555212 A JP2014555212 A JP 2014555212A JP 2015505553 A5 JP2015505553 A5 JP 2015505553A5
- Authority
- JP
- Japan
- Prior art keywords
- particle size
- administration
- dosage form
- active compound
- pharmaceutical dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000743.0 | 2012-02-03 | ||
| EP12000743 | 2012-02-03 | ||
| PCT/EP2013/051979 WO2013113857A1 (en) | 2012-02-03 | 2013-02-01 | (1r,4r)-6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505553A JP2015505553A (ja) | 2015-02-23 |
| JP2015505553A5 true JP2015505553A5 (enExample) | 2016-03-31 |
| JP6126134B2 JP6126134B2 (ja) | 2017-05-10 |
Family
ID=47628188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555212A Active JP6126134B2 (ja) | 2012-02-03 | 2013-02-01 | 線維筋痛症および慢性疲労症候群の治療のための、（１ｒ，４ｒ）−６’−フルオロ−（Ｎ−メチル−またはＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130202701A1 (enExample) |
| EP (1) | EP2809320B1 (enExample) |
| JP (1) | JP6126134B2 (enExample) |
| KR (1) | KR102061482B1 (enExample) |
| CN (1) | CN104168897B (enExample) |
| AU (1) | AU2013214223B2 (enExample) |
| BR (1) | BR112014019136A8 (enExample) |
| CA (1) | CA2863572C (enExample) |
| CY (1) | CY1118799T1 (enExample) |
| DK (1) | DK2809320T3 (enExample) |
| EA (1) | EA025500B1 (enExample) |
| ES (1) | ES2629211T3 (enExample) |
| HR (1) | HRP20170581T1 (enExample) |
| IL (1) | IL233871B (enExample) |
| LT (1) | LT2809320T (enExample) |
| MX (1) | MX353740B (enExample) |
| NZ (1) | NZ629800A (enExample) |
| PL (1) | PL2809320T3 (enExample) |
| PT (1) | PT2809320T (enExample) |
| RS (1) | RS56097B1 (enExample) |
| SI (1) | SI2809320T1 (enExample) |
| WO (1) | WO2013113857A1 (enExample) |
| ZA (1) | ZA201406447B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2974578C (en) | 2015-01-23 | 2020-11-17 | Grunenthal Gmbh | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10360792A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| WO2005092895A2 (en) * | 2004-03-29 | 2005-10-06 | Pfizer Japan Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists |
| US20070282007A1 (en) * | 2006-05-31 | 2007-12-06 | Sepracor Inc. | TREATMENT OF PAIN DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND ITS FORMAMIDE |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
-
2013
- 2013-02-01 MX MX2014008865A patent/MX353740B/es active IP Right Grant
- 2013-02-01 ES ES13701807.3T patent/ES2629211T3/es active Active
- 2013-02-01 WO PCT/EP2013/051979 patent/WO2013113857A1/en not_active Ceased
- 2013-02-01 CN CN201380007809.0A patent/CN104168897B/zh not_active Expired - Fee Related
- 2013-02-01 US US13/757,223 patent/US20130202701A1/en not_active Abandoned
- 2013-02-01 HR HRP20170581TT patent/HRP20170581T1/hr unknown
- 2013-02-01 JP JP2014555212A patent/JP6126134B2/ja active Active
- 2013-02-01 PL PL13701807T patent/PL2809320T3/pl unknown
- 2013-02-01 EA EA201400857A patent/EA025500B1/ru not_active IP Right Cessation
- 2013-02-01 SI SI201330672A patent/SI2809320T1/sl unknown
- 2013-02-01 LT LTEP13701807.3T patent/LT2809320T/lt unknown
- 2013-02-01 PT PT137018073T patent/PT2809320T/pt unknown
- 2013-02-01 BR BR112014019136A patent/BR112014019136A8/pt not_active Application Discontinuation
- 2013-02-01 DK DK13701807.3T patent/DK2809320T3/en active
- 2013-02-01 NZ NZ629800A patent/NZ629800A/en not_active IP Right Cessation
- 2013-02-01 RS RS20170602A patent/RS56097B1/sr unknown
- 2013-02-01 EP EP13701807.3A patent/EP2809320B1/en active Active
- 2013-02-01 KR KR1020147024696A patent/KR102061482B1/ko not_active Expired - Fee Related
- 2013-02-01 CA CA2863572A patent/CA2863572C/en not_active Expired - Fee Related
- 2013-02-01 AU AU2013214223A patent/AU2013214223B2/en not_active Ceased
-
2014
- 2014-07-30 IL IL233871A patent/IL233871B/en active IP Right Grant
- 2014-09-02 ZA ZA2014/06447A patent/ZA201406447B/en unknown
-
2017
- 2017-04-03 CY CY20171100395T patent/CY1118799T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009512663A5 (enExample) | ||
| CY1124878T1 (el) | Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης | |
| WO2013132457A3 (en) | Nanocrystalline solid dispersion compositions and process of preparation thereof | |
| HRP20250776T1 (hr) | Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa | |
| JP2016065086A5 (enExample) | ||
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| JP2016516808A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| HN2011000864A (es) | Particulas inhalables que comprenden tiotropio | |
| ECSP11011289A (es) | Formulaciones galénicas de compuestos orgánicos | |
| JP2015510916A5 (enExample) | ||
| JP2014221827A5 (enExample) | ||
| JP2016513625A5 (enExample) | ||
| CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| JP2015520241A5 (enExample) | ||
| JP2016540000A5 (enExample) | ||
| JP2014062109A5 (enExample) | ||
| JP2015505553A5 (enExample) | ||
| WO2014167579A3 (en) | Stable pharmaceutical compositions of tadalafil | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| JP2016523943A5 (enExample) | ||
| JP2015536957A5 (enExample) | ||
| EA202090172A1 (ru) | Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью | |
| TR200907914A2 (tr) | Kortlkosteroid içeren kuru toz formunda farmasötik bileşim. |